- Home
- LH vs GH Comparison
LH vs GH Comparison
Compare LH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | GH |
|---|---|---|
| Founded | 1971 | 2011 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 22.9B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LH | GH |
|---|---|---|
| Price | $368.33 | $150.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 26 |
| Target Price | ★ $382.25 | $202.24 |
| AVG Volume (30 Days) | 736.8K | ★ 1.7M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ 18.33 | 6.74 |
| EPS | ★ 10.22 | N/A |
| Revenue | ★ $13,951,700,000.00 | $982,021,000.00 |
| Revenue This Year | $6.20 | $38.41 |
| Revenue Next Year | $5.39 | $35.18 |
| P/E Ratio | $35.99 | ★ N/A |
| Revenue Growth | 7.25 | ★ 32.88 |
| 52 Week Low | $245.00 | $74.55 |
| 52 Week High | $371.00 | $191.05 |
Technical Indicators
Market Signals| Indicator | LH | GH |
|---|---|---|
| Relative Strength Index (RSI) | 70.04 | 34.54 |
| Support Level | $256.51 | $140.86 |
| Resistance Level | $371.00 | $177.55 |
| Average True Range (ATR) | 11.47 | 9.94 |
| MACD | 3.03 | -2.28 |
| Stochastic Oscillator | 88.92 | 20.79 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.